Palatin Technologies, Inc.

PTN
$14.48 (+ $0.03 + 0.21%)
Last updated: 2026-05-27 20:14 UTC
PTN Metrics
Exchange
🇺🇸 NYSE XASE
NYSE Mkt LLCUnited StatesAmerica/New_York
SectorHealthcare
IndustryBiotechnology
ISINUS6960776010
CUSIP696077601
Market Price14.47
Dividend Yield N/A
Dividend Growth
1YN/A
3YN/A
5YN/A
10YN/A
Annual Dividend N/A
Latest Payout ($)N/A
Latest Payout DateN/A
Dividend FrequencyNone
P/E RatioN/A
EPS-7.76
Market Cap$27.2M
Book Value0.41
Price to Book39.312
Beta-0.2
52w High72.5
52w Low2.0
Next Earnings DateN/A

Palatin Technologies, Inc. trades under ticker PTN on NYSE as a stock. Use this page to review stock price, dividends, and price history. The page also shows Healthcare exposure. Identifiers: ISIN US6960776010, CUSIP 696077601.

About the Company
Palatin Technologies, Inc., a biopharmaceutical company, develops first-in-class medicines based on molecules that modulate the activity of the melanocortin receptor system in the United States. It is developing oral small molecule PL7737 MC4R agonist in preclinical studies; long-acting peptide MC4R agonists; and Bremelanotide co-administration with Tirzepatide to treat obesity in Phase 2 trial, as well as Bremelanotide co-formulated with a PDE5i for the treatment of ED in patients not adequately responsive to PDE5i monotherapy. The company also develops PL9643 for dry eye disease and anti-inflammatory ocular indications; and oral PL8177 for the treatment inflammatory bowel diseases. Palatin Technologies, Inc. was incorporated in 1986 and is based in Monmouth Junction, New Jersey.
Price History